67 related articles for article (PubMed ID: 8630232)
21. Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation.
Bostwick DG
Anat Pathol; 1998; 3():1-16. PubMed ID: 10389579
[No Abstract] [Full Text] [Related]
22. Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and low-affinity NGF receptors.
Sortino MA; Condorelli F; Vancheri C; Chiarenza A; Bernardini R; Consoli U; Canonico PL
Mol Endocrinol; 2000 Jan; 14(1):124-36. PubMed ID: 10628752
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
Thelen P; Wuttke W; Jarry H; Grzmil M; Ringert RH
J Urol; 2004 May; 171(5):1934-8. PubMed ID: 15076315
[TBL] [Abstract][Full Text] [Related]
24. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
25. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
26. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells.
Andrews J; Djakiew D; Krygier S; Andrews P
Cancer Chemother Pharmacol; 2002 Oct; 50(4):277-84. PubMed ID: 12357301
[TBL] [Abstract][Full Text] [Related]
27. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP.
Young CY; Montgomery BT; Andrews PE; Qui SD; Bilhartz DL; Tindall DJ
Cancer Res; 1991 Jul; 51(14):3748-52. PubMed ID: 1712248
[TBL] [Abstract][Full Text] [Related]
28. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
Schatten H; Ripple M; Balczon R; Weindruch R; Chakrabarti A; Taylor M; Hueser CN
J Cell Biochem; 2000 Jan; 76(3):463-77. PubMed ID: 10649443
[TBL] [Abstract][Full Text] [Related]
29. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
Gleave ME; Sato N; Sadar M; Yago V; Bruchovsky N; Sullivan L
J Cell Biochem; 1998 Jun; 69(3):271-81. PubMed ID: 9581866
[TBL] [Abstract][Full Text] [Related]
30. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
31. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells.
Lee MS; Igawa T; Yuan TC; Zhang XQ; Lin FF; Lin MF
Oncogene; 2003 Feb; 22(5):781-96. PubMed ID: 12569372
[TBL] [Abstract][Full Text] [Related]
32. Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation.
Nunlist EH; Dozmorov I; Tang Y; Cowan R; Centola M; Lin HK
J Steroid Biochem Mol Biol; 2004 Jul; 91(3):157-70. PubMed ID: 15276623
[TBL] [Abstract][Full Text] [Related]
33. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
34. Growth inhibitory activity of lemnabourside on human prostate cancer cells.
Liu WK; Wong NL; Huang HM; Ho JK; Zhang WH; Che CT
Life Sci; 2002 Jan; 70(7):843-53. PubMed ID: 11837251
[TBL] [Abstract][Full Text] [Related]
35. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
Grigoryev DN; Long BJ; Nnane IP; Njar VC; Liu Y; Brodie AM
Br J Cancer; 1999 Oct; 81(4):622-30. PubMed ID: 10574247
[TBL] [Abstract][Full Text] [Related]
36. Evidence for a role of glucuronosyltransferase in the regulation of androgen action in the human prostatic cancer cell line LNCaP.
Guillemette C; Hum DW; Bélanger A
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):225-31. PubMed ID: 8645632
[TBL] [Abstract][Full Text] [Related]
37. Equol an isoflavonoid: potential for improved prostate health, in vitro and in vivo evidence.
Lund TD; Blake C; Bu L; Hamaker AN; Lephart ED
Reprod Biol Endocrinol; 2011 Jan; 9():4. PubMed ID: 21232127
[TBL] [Abstract][Full Text] [Related]
38. LY191704 inhibits type I steroid 5 alpha-reductase in human scalp.
Neubauer BL; Gray HM; Hanke CW; Hirsch KS; Hsiao KC; Jones CD; Kumar MV; Lawhorn DE; Lindzey J; McQuaid L; Tindall DJ; Toomey RE; Yao RC; Audia JE
J Clin Endocrinol Metab; 1996 Jun; 81(6):2055-60. PubMed ID: 8964828
[TBL] [Abstract][Full Text] [Related]
39. Characterization of ALVA-41 cells, a new human prostatic cancer cell line.
Nakhla AM; Rosner W
Steroids; 1994 Oct; 59(10):586-9. PubMed ID: 7533340
[TBL] [Abstract][Full Text] [Related]
40. Stable expression of human 5alpha-reductase type II in COS1 cells due to chromosomal gene integration: a novel tool for inhibitor identification.
Reichert W; Michel A; Hartmann RW; Jose J
J Steroid Biochem Mol Biol; 2001 Sep; 78(3):275-84. PubMed ID: 11595508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
